Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia.
Daptomycin is a Food and Drug Administration-approved alternative to vancomycin for the treatment of serious methicillin-resistant Staphylococcus aureus infections in adults. Treatment failure with daptomycin is increasingly reported in adults, but data in children are limited. We report an adolescent patient with severe burn injuries who had persistent methicillin-resistant Staphylococcus aureus bacteremia and rapidly developed nonsusceptibility to daptomycin. We review the relevant literature.
Jacobson
Lara M
LM
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ljacob19@jhmi.edu
Milstone
Aaron M
AM
Zenilman
Jonathan
J
Carroll
Karen C
KC
Arav-Boger
Ravit
R
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology; D017576:Daptomycin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005839:Gentamicins / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology*; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D014640:Vancomycin; D017576:Daptomycin